Dopamine, by acting through Its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation

American Journal of Pathology

Volumn 177, Issue 6, 2010, Pages 2701-2707

  Ganguly, Subhalakshmi ^a   Basu, Biswarup ^a   Shome, Saurav ^a   Jadhav, Tushar ^a   Roy, Sudipta ^b   Majumdar, Jahar ^a   Dasgupta, Partha Sarathi ^a   Basu, Sujit ^c,d  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b QUADRA MEDICAL SERVICES PVT LTD   (India)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; KRUPPEL LIKE FACTOR 4; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; KRUPPEL LIKE FACTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH ADENOCARCINOMA; STOMACH CANCER; UPREGULATION; ADENOCARCINOMA; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; CELL PROLIFERATION; CELLS, CULTURED; DOPAMINE; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTORS, DOPAMINE D2; STOMACH NEOPLASMS; UP-REGULATION;

EID: 78650184684     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100617     Document Type: Article

References (48)

1. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY: Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001, 37:2257-2263
2. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T: Impact of insulin like growth factor type 1 receptor, epidermal growth factor receptor and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008, 14:3022-3029
3. Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28:20-47
4. Hwang PH, Kim SY, Lee JC, Kim SJ, Yi HK, Lee DY: PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells. Exp Mol Med 2005, 37:391-398
5. Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D, Ling WL, Cannon-Carlson S, Greenberg R, Ramos RA, Shields R, Presta L, Brams P, Bishop WR, Pachter JA: Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005, 4:1214-1221
6. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK: Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007, 6:1357-1367
7. Ryan PD, Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008, 13:16-24
8. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562
9. Adachi Y, Yamamoto H, Imsumran A, Oka T, Oki M, Nosho K, Min Y, Shinomura Y, Lee C-T, Carbone DP, Imai K: Insulin-like growth factor-I receptor as a candidate for a novel molecular target in gastrointestinal cancers. Dig Endosc 2006, 18:245-251
10. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI: Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005, 12:S99-S111 (Pubitemid 41395417)
11. Chitnis MM, Yuen JSP, Protheroe AS, Pollak M, Macaulay VM: The type1insulin-like growth factor receptor pathway. Clin Cancer Res 2008, 14:6364-6370
12. Lopez T, Hanahan D: Elevated levels of IGF-I receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002, 1:339-353
13. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA: Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26:1636-1644
14. Eisenhofer G, Åneman A, Friberg P, Hooper D, Fåndriks L, Lonroth H, Hunyady B, Mezey E: Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997, 82:3864-3871
15. Mezey É, Eisenhofer G, Hansson S, Hunyady B, Hoffman BJ: Dopamine produced by the stomach may act as a paracrine/autocrine hormone in the rat. Neuroendocrinology 1998, 67:336-348
16. Flemstrom G, Safsten B, Jedstedt G: Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds. Gastroenterology 1993, 104:825-833
17. Finkel Y, Eklof AC, Granquist L, Soares-da-Silva P, Bertorello AM: Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats. Gastroenterology 1994, 107:675-679 (Pubitemid 24265513)
18. Glavin GB, Szabo S: Dopamine in gastrointestinal disease. Dig Dis Sci 1990, 35:1153-1161
19. Haskel Y, Hanani M: Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Dig Dis Sci 1994, 39:2364-2367
20. Glavin GB, Hall AM: Central and peripheral dopamine D1/DA1 receptor modulation of gastric secretion and experimental gastric mucosal injury. Gen Pharmacol 1995, 26:1277-1279
21. Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG: Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 1985, 37:165-216
22. Hernandez DE, Mason GA, Walker CH, Valenzuela JE: Dopamine receptors in human gastrointestinal mucosa. Life Sci 1987, 41:2717-2723
23. Kobayashi M, Iaccarino C, Saiardi A, Heidt V, Bozzi Y, Picetti R, Vitale C, Westphal H, Drago J, Borrelli E: Simultaneous absence of dopamine D1 and D2 receptor-mediated signaling is lethal in mice. Proc Natl Acad Sci USA 2004, 101:11465-11470
24. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S: Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004, 10:4349-4356
25. Kang W, Nielsen O, Fenger C, Leslie G, Holmskov U, Reid KB: Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiation-like process and its association with human gastric cancer. Carcinogenesis 2005, 26:1129-1137
26. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, Mehren MV, Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105:8387-8392
27. Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Matsubara O, Hiraide H, Mochizuki H: Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci 2006, 97:597-604
28. Takeshima E, Tomimori K, Kawakami H, Ishikawa C, Sawada S, Tomita M, Senba M, Kinjo F, Mimuro H, Sasakawa C, Fujita J, Mori N: NF-κB activation by Helicobacter pylori requires Akt-mediated phosphorylation of p65. BMC Microbiol 2009, 9:36
29. Kwon MJ, Nam TJ: Porphyran induces apoptosis related signal pathway in AGS gastric cancer cell lines. Life Sci 2006, 79:1956-1962
30. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C: In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006, 66:362-371
31. Ubagai T, Kikuchi T, Fukusato T, Ono Y: Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis. Toxicol In Vitro 2010, 24:783-789
32. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001, 91:173-179
33. Xin M, Deng X: Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005, 280:10781-10789 (Pubitemid 40395941)
34. Pallares J, Llobet D, Santacana M, Eritja N, Velasco A, Cuevas D, Lopez S, Palomar-Asenjo V, Yeramian A, Dolcet X, Matias-Guiu X: CK2β is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol 2009, 174:287-296
35. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG: An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273
36. Gao N, Zhang Z, Jiang BH, Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003, 310:1124-1132
37. Mahatan CS, Kaestner KH, Geiman DE, Yang VW: Characterization of the structure and regulation of the murine gene encoding gut-enriched Krüppel-like factor (Krüppel-like factor 4). Nucleic Acids Res 1999, 27:4562-4569
38. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, Wu TT, Huang S, Xie K: Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 2005, 65:2746-2754
39. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518
40. Mitsiades CS, Mitsiades N: Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther 2005, 5:487-499
41. Larsson O, Girnita A, Girnita L: Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 2005, 92:2097-2101
42. Jiang Y, Wang L, Gong W, Wei D, Le Xiangdong, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K: A high expression level of Insulin-like growth factor 1 receptor is associated with increased expression of transcription factor sp1 and regional lymph node metastasis in human gastric cancer. Clin Exp Metastasis 2004, 21:755-764
43. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW: The gut-enriched Krüppel-like factor (Krüppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol chem 2000, 275:18391-18398
44. 1/S progression of the cell cycle. J Biol Chem 2001, 276:30423-30428
45. Shie SL, Chen ZY, Fiu M, Pestell RG, Tsing CC: Gut enriched Kruppel like factor represses cyclin D1 promoter activity through sp1 motif. Nucleic acid Res 2000, 28:2969-2976
46. 1/S cell cycle arrest in response to DNA damage. J Biol Chem 2003, 278:2101-2105
47. Kleespies A, Jauch KW, Bruns CJ: Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug Resist Updat 2006, 9:1-18
48. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I: Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009, 9:66-76